Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis

References

• Barturen G, Beretta L, Cervera R, Van Vollenhoven R, Alarcón-Riquelme ME. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol. 2018;14:75. doi:10.1038/nrrheum.2017.22029362467
   PubMed Web of Science ®Google Scholar
• Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994;120(1):26–34. doi:10.7326/0003-4819-120-1-199401010-000058250453
   PubMed Web of Science ®Google Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265–S272. doi:10.1186/ar57812110146
   PubMedGoogle Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372. doi:10.1001/jama.2018.1310330285183
   PubMed Web of Science ®Google Scholar
• Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology. 2007;46(2):350–357. doi:10.1093/rheumatology/kel25316908509
   PubMed Web of Science ®Google Scholar
• Gabriel Sherine E, Crowson Cynthia S, Kremers Hilal M, et al. Survival in rheumatoid arthritis: a population‐based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1):54–58. doi:10.1002/art.1070512528103
   PubMed Web of Science ®Google Scholar
• Malviya G, Salemi S, Laganà B, Diamanti AP, D’Amelio R, Signore A. Biological therapies for rheumatoid arthritis: progress to date. BioDrugs. 2013;27(4):329–345. doi:10.1007/s40259-013-0021-x23558378
   PubMed Web of Science ®Google Scholar
• Chen S-J, Lin G-J, Chen J-W, et al. Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis. Int J Mol Sci. 2019;20(6):1332. doi:10.3390/ijms20061332
   Web of Science ®Google Scholar
• Scherer HU, Huizinga TWJ, Krönke G, Schett G, Toes REM. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14:157. doi:10.1038/nrrheum.2018.1029416134
   PubMed Web of Science ®Google Scholar
• Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3. doi:10.1136/annrheumdis-2013-20431724072562
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960. doi:10.1136/annrheumdis-2016-21071528264816
   PubMed Web of Science ®Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–361. doi:10.1038/nature0166112748655
   PubMed Web of Science ®Google Scholar
• Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615–633. doi:10.1016/j.biopha.2017.05.05528582758
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Malmström V, Burkhardt H. Autoimmune priming, tissue attack and chronic inflammation — the three stages of rheumatoid arthritis. Eur J Immunol. 2014;44(6):1593–1599. doi:10.1002/eji.v44.624737176
   PubMed Web of Science ®Google Scholar
• Sidiropoulos PI, Goulielmos G, Voloudakis GK, Petraki E, Boumpas DT. Inflammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis. 2008;67(10):1382. doi:10.1136/ard.2007.07801417921182
   PubMed Web of Science ®Google Scholar
• Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6(3):315–325. doi:10.1016/S1074-7613(00)80334-99075932
   PubMed Web of Science ®Google Scholar
• Jung MS, Lee J, Baek YS, et al. Fraxinellone attenuates rheumatoid inflammation in mice. Int J Mol Sci. 2018;19(3):829. doi:10.3390/ijms19030829
   Web of Science ®Google Scholar
• Myers LK, Stuart JM, Kang AH. A CD4 cell is capable of transferring suppression of collagen-induced arthritis. J Immunol. 1989;143(12):3976–3980.2574207
   PubMed Web of Science ®Google Scholar
• Pöllinger B. IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis. J Mol Med (Berl). 2012;90(6):613–624. doi:10.1007/s00109-011-0841-422231742
   PubMed Web of Science ®Google Scholar
• Kelchtermans H, Geboes L, Mitera T, Huskens D, Leclercq G, Matthys P. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann Rheum Dis. 2009;68(5):744. doi:10.1136/ard.2007.08606618480308
   PubMed Web of Science ®Google Scholar
• Dulic S, Vásárhelyi Z, Sava F, et al. T-Cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy. Mediators Inflamm. 2017;2017:6894374. doi:10.1155/2017/689437429209104
   PubMed Web of Science ®Google Scholar
• Navegantes KC, de Souza Gomes R, Pereira PAT, Czaikoski PG, Azevedo CHM, Monteiro MC. Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity. J Transl Med. 2017;15(1):36. doi:10.1186/s12967-017-1141-828202039
   PubMed Web of Science ®Google Scholar
• Milanova V, Ivanovska N, Dimitrova P. TLR2 elicits IL-17-mediated RANKL expression, IL-17, and OPG production in neutrophils from arthritic mice. Mediators Inflamm. 2014;2014:14. doi:10.1155/2014/643406
   Web of Science ®Google Scholar
• Pelletier M, Maggi L, Micheletti A, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115(2):335–343. doi:10.1182/blood-2009-04-21608519890092
   PubMed Web of Science ®Google Scholar
• Jaeger BN, Donadieu J, Cognet C, et al. Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. J Exp Med. 2012;209(3):565–580. doi:10.1084/jem.2011190822393124
   PubMed Web of Science ®Google Scholar
• Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–2971. doi:10.1111/febs.1446629637711
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127. doi:10.1016/S1074-7613(00)80165-X10714678
   PubMed Web of Science ®Google Scholar
• Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000;52(1):145.10699158
   PubMed Web of Science ®Google Scholar
• Miller MC, Mayo KH. Chemokines from a structural perspective. Int J Mol Sci. 2017;18(10):2088. doi:10.3390/ijms18102088
   PubMed Web of Science ®Google Scholar
• Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–644. doi:10.1038/385640a09024663
   PubMed Web of Science ®Google Scholar
• Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol. 2000;1(4):298–304. doi:10.1038/7973811017100
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32(1):659–702. doi:10.1146/annurev-immunol-032713-12014524655300
   PubMed Web of Science ®Google Scholar
• Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors. Nat Rev Immunol. 2013;13(11):815–829. doi:10.1038/nri354424319779
   PubMed Web of Science ®Google Scholar
• Weber M, Blair E, Simpson CV, et al. The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol Biol Cell. 2004;15(5):2492–2508. doi:10.1091/mbc.e03-09-063415004236
   PubMed Web of Science ®Google Scholar
• Fra AM, Locati M, Otero K, et al. Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol. 2003;170(5):2279. doi:10.4049/jimmunol.170.5.227912594248
   PubMed Web of Science ®Google Scholar
• Ridiandries A, Tan JTM, Bursill CA. The role of CC-chemokines in the regulation of angiogenesis. Int J Mol Sci. 2016;17(11):1856. doi:10.3390/ijms17111856
   Web of Science ®Google Scholar
• Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7(5):a016303. doi:10.1101/cshperspect.a01630325635046
   PubMed Web of Science ®Google Scholar
• Lian J, Luster AD. Chemokine-guided cell positioning in the lymph node orchestrates the generation of adaptive immune responses. Curr Opin Cell Biol. 2015;36:1–6. doi:10.1016/j.ceb.2015.05.00326067148
   PubMed Web of Science ®Google Scholar
• Comerford I, Kara EE, McKenzie DR, McColl SR. Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking. Br J Haematol. 2014;164(3):329–341. doi:10.1111/bjh.2014.164.issue-324164387
   PubMed Web of Science ®Google Scholar
• Rolin J, Maghazachi AA. Implications of chemokines, chemokine receptors, and inflammatory lipids in atherosclerosis. J Leukoc Biol. 2014;95(4):575–585. doi:10.1189/jlb.111357124493826
   PubMed Web of Science ®Google Scholar
• Rolin J, Maghazachi AA. Implications of chemokine receptors and inflammatory lipids in cancer. Immunotargets Ther. 2013;3:9–18. doi:10.2147/ITT.S3204927471696
   PubMedGoogle Scholar
• Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol. 2003;15(1):15–21. doi:10.1016/S1044-5323(02)00124-012495637
   PubMed Web of Science ®Google Scholar
• Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 2005;52(3):710–721. doi:10.1002/(ISSN)1529-013115751074
   PubMed Web of Science ®Google Scholar
• White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation—therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65(1):47. doi:10.1124/pr.111.00507423300131
   PubMed Web of Science ®Google Scholar
• Chou RC, Kim ND, Sadik CD, et al. Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity. 2010;33(2):266–278. doi:10.1016/j.immuni.2010.07.01820727790
   PubMed Web of Science ®Google Scholar
• Greisen SR, Schelde KK, Rasmussen TK, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity’. Arthritis Res Ther. 2014;16(5):434. doi:10.1186/s13075-014-0434-z25249397
   PubMed Web of Science ®Google Scholar
• Yeo L, Adlard N, Biehl M, et al. Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):763. doi:10.1136/annrheumdis-2014-20692125858640
   PubMed Web of Science ®Google Scholar
• Yoshida K, Korchynskyi O, Tak PP, et al. Citrullination of epithelial neutrophil–activating peptide 78/CXCL5 results in conversion from a non–monocyte-recruiting chemokine to a monocyte-recruiting chemokine. Arthritis Rheumatol. 2014;66(10):2716–2727. doi:10.1002/art.v66.1024943990
   PubMed Web of Science ®Google Scholar
• Sucur A, Jajic Z, Artukovic M, et al. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells. Arthritis Res Ther. 2017;19(1):142. doi:10.1186/s13075-017-1337-628619088
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Fuh L-J, Huang -C-C, et al. Enhancement of CCL2 expression and monocyte migration by CCN1 in osteoblasts through inhibiting miR-518a-5p: implication of rheumatoid arthritis therapy. Sci Rep. 2017;7(1):421. doi:10.1038/s41598-017-00513-028341837
   PubMed Web of Science ®Google Scholar
• Bao J, Liu W, Bao Y-X. Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis. Cent Eur J Immunol. 2014;39(2):170–173. doi:10.5114/ceji.2014.4371726155119
   PubMed Web of Science ®Google Scholar
• Eriksson C, Rantapää-Dahlqvist S, Sundqvist KG. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42(4):260–265. doi:10.3109/03009742.2012.75493723379516
   PubMed Web of Science ®Google Scholar
• Katrib A, Tak PP, Bertouch JV, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology. 2001;40(9):988–994. doi:10.1093/rheumatology/40.9.98811561108
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Vegvari A, Szabo Z, Koch AE. Chemokines and chemokine receptors in arthritis. Front Biosci (Schol Ed). 2010;2:153–167. doi:10.2741/s5320036936
   PubMedGoogle Scholar
• Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992;90(3):772–779. doi:10.1172/JCI1159501522232
   PubMed Web of Science ®Google Scholar
• Hatano Y, Kasama T, Iwabuchi H, et al. Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis. Ann Rheum Dis. 1999;58(5):297–302. doi:10.1136/ard.58.5.29710225815
   PubMed Web of Science ®Google Scholar
• Xuan W, Feng X, Qian C, et al. Osteoclast differentiation gene expression profiling reveals chemokine CCL4 mediates RANKL-induced osteoclast migration and invasion via PI3K pathway. Cell Biochem Funct. 2017;35(3):171–177. doi:10.1002/cbf.326028370169
   PubMed Web of Science ®Google Scholar
• Bahlas S, Damiati L, Dandachi N, Sait H, Alsefri M, Pushparaj PN. Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using luminex multiple analyte profiling technology for precision medicine. Clin Exp Rheumatol. 2019;37(1):112–119.
   Web of Science ®Google Scholar
• van Hooij A, Boeters DM, Tjon Kon Fat EM, et al. Longitudinal IP-10 serum levels are associated with the course of disease activity and remission in patients with rheumatoid arthritis. Clin Vaccine Immunol. 2017;24(8):e00060–e00017. doi:10.1128/CVI.00060-1728592626
   PubMedGoogle Scholar
• Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol. 1998;28(11):3696–3705. doi:10.1002/(ISSN)1521-41419842912
   PubMed Web of Science ®Google Scholar
• Má G-L, Sánchez-Madrid F, Rodríguez-Frade JM, et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest. 2001;81(3):409–418.11310833
   PubMed Web of Science ®Google Scholar
• Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine. 2018;109:24–28. doi:10.1016/j.cyto.2018.02.01229449068
   PubMed Web of Science ®Google Scholar
• Di Domenicantonio A. Rheumatoid arthritis and the alpha-chemokine IP-10. Clin Ter. 2014;165(6):e447–e451. doi:10.7417/CT.2014.179125524204
   PubMedGoogle Scholar
• Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101(4):746–754. doi:10.1172/JCI14229466968
   PubMed Web of Science ®Google Scholar
• Mohan K, Issekutz TB. blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol. 2007;179(12):8463. doi:10.4049/jimmunol.179.12.846318056393
   PubMed Web of Science ®Google Scholar
• Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479–489. doi:10.1038/nri280020559326
   PubMed Web of Science ®Google Scholar
• Morand EF, Leech M. Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci. 2005;10:12–22. doi:10.2741/150115576336
   PubMed Web of Science ®Google Scholar
• Van Raemdonck K, Umar S, Palasiewicz K, et al. CCL21/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis. Cell Mol Life Sci. 2019. doi:10.1007/s00018-019-03235-w
   Web of Science ®Google Scholar
• Ellingsen T, Hansen I, Thorsen J, et al. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression. Scand J Rheumatol. 2014;43(2):91–100. doi:10.3109/03009742.2013.80314923980529
   PubMed Web of Science ®Google Scholar
• Sellam J, Rouanet S, Hendel-Chavez H, et al. CCL19, a B Cell chemokine, is related to the decrease of blood memory B Cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(9):2253–2261. doi:10.1002/art.3802323740460
   PubMed Web of Science ®Google Scholar
• Lee J, Park C, Kim HJ, et al. Stimulation of osteoclast migration and bone resorption by C-C chemokine ligands 19 and 21. Exp Mol Med. 2017;49(7):e358. doi:10.1038/emm.2017.10028729639
   PubMed Web of Science ®Google Scholar
• Yokoyama W, Kohsaka H, Kaneko K, et al. Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Res Ther. 2014;16(5):445. doi:10.1186/s13075-014-0445-925248373
   PubMed Web of Science ®Google Scholar
• Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204(12):2803. doi:10.1084/jem.2007139718025126
   PubMed Web of Science ®Google Scholar
• Paulissen SMJ, van Hamburg JP, Dankers W, Lubberts E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine. 2015;74(1):43–53. doi:10.1016/j.cyto.2015.02.00225828206
   PubMed Web of Science ®Google Scholar
• Maggi L, Santarlasci V, Capone M, et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol. 2012;42(12):3180–3188. doi:10.1002/eji.20124264822965818
   PubMed Web of Science ®Google Scholar
• Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876–2885. doi:10.1002/art.v62:1020583102
   PubMed Web of Science ®Google Scholar
• Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17–producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58(3):875–887. doi:10.1002/(ISSN)1529-013118311821
   PubMed Web of Science ®Google Scholar
• Li X, Yuan F-L, Lu W-G, et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun. 2010;397(2):131–135. doi:10.1016/j.bbrc.2010.05.11120513356
   PubMed Web of Science ®Google Scholar
• Ruth JH, Shahrara S, Park CC, et al. Role of macrophage inflammatory protein-3α and its ligand CCR6 in rheumatoid arthritis. Lab Invest. 2003;83(4):579–588. doi:10.1097/01.LAB.0000062854.30195.5212695561
   PubMed Web of Science ®Google Scholar
• Lee AYS, Körner H. CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis. Immunol Cell Biol. 2014;92(4):354–358. doi:10.1038/icb.2013.9724394994
   PubMed Web of Science ®Google Scholar
• Kochi Y, Okada Y, Suzuki A, et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet. 2010;42(6):515–519. doi:10.1038/ng.58320453841
   PubMed Web of Science ®Google Scholar
• Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42(6):508–514. doi:10.1038/ng.58220453842
   PubMed Web of Science ®Google Scholar
• Lisignoli G, Piacentini A, Cristino S, et al. CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients. J Cell Physiol. 2007;210(3):798–806. doi:10.1002/(ISSN)1097-465217133360
   PubMed Web of Science ®Google Scholar
• Matsui T, Akahoshi T, Namai R, et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin Exp Immunol. 2001;125(1):155–161. doi:10.1046/j.1365-2249.2001.01542.x11472439
   PubMed Web of Science ®Google Scholar
• Haudenschild DR, Nguyen B, Chen J, D’Lima DD, Lotz MK. Rho kinase–dependent CCL20 induced by dynamic compression of human chondrocytes. Arthritis Rheum. 2008;58(9):2735–2742. doi:10.1002/art.v58:918759278
   PubMed Web of Science ®Google Scholar
• Page G, Lebecque S, Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol. 2002;168(10):5333–5341. doi:10.4049/jimmunol.168.10.533311994492
   PubMed Web of Science ®Google Scholar
• Kim H-R, Kim K-W, Kim B-M, Jung H-G, Cho M-L, Lee S-H. Reciprocal activation of CD4+ T cells and synovial fibroblasts by stromal cell–derived factor 1 promotes RANKL expression and osteoclastogenesis in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(3):538–548. doi:10.1002/art.v66.324574213
   PubMed Web of Science ®Google Scholar
• Kanbe K, Chiba J, Inoue Y, Taguchi M, Yabuki A. SDF-1 and CXCR4 in synovium are associated with disease activity and bone and joint destruction in patients with rheumatoid arthritis treated with golimumab. Mod Rheumatol. 2016;26(1):46–50. doi:10.3109/14397595.2015.105408825995033
   PubMed Web of Science ®Google Scholar
• Buckley CD, Amft N, Bradfield PF, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000;165(6):3423–3429. doi:10.4049/jimmunol.165.6.342310975862
   PubMed Web of Science ®Google Scholar
• Bugatti S, Manzo A, Vitolo B, et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology (Oxford). 2014;53(10):1886–1895. doi:10.1093/rheumatology/keu16324764267
   PubMed Web of Science ®Google Scholar
• Allam SI, Sallam RA, Elghannam DM, El-Ghaweet AI. Clinical significance of serum B cell chemokine (CXCL13) in early rheumatoid arthritis patients. Egypt Rheumatol. 2019;41(1):11–14. doi:10.1016/j.ejr.2018.04.003
   Web of Science ®Google Scholar
• Han BK, Kuzin I, Gaughan JP, Olsen NJ, Bottaro A. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Arthritis Res Ther. 2016;18:93. doi:10.1186/s13075-016-0995-027102921
   PubMed Web of Science ®Google Scholar
• Jones JD, Hamilton BJ, Challener GJ, et al. Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther. 2014;16(2):R103–R103. doi:10.1186/ar455224766912
   PubMed Web of Science ®Google Scholar
• Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005;52(10):3004–3014. doi:10.1002/(ISSN)1529-013116200580
   PubMed Web of Science ®Google Scholar
• van der Voort R, van Lieshout AWT, Toonen LWJ, et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum. 2005;52(5):1381–1391. doi:10.1002/art.2100415880344
   PubMed Web of Science ®Google Scholar
• Ruth JH, Volin MV, Haines GK 3rd, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001;44(7):1568–1581. doi:10.1002/(ISSN)1529-013111465708
   PubMed Web of Science ®Google Scholar
• Yoneda O, Imai T, Goda S, et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol. 2000;164(8):4055–4062. doi:10.4049/jimmunol.164.8.405510754298
   PubMed Web of Science ®Google Scholar
• Choi J, Selmi C, Leung PSC, Kenny TP, Roskams T, Gershwin ME. Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis. Expert Rev Clin Immunol. 2016;12(6):661–672. doi:10.1586/1744666X.2016.114795626821815
   PubMed Web of Science ®Google Scholar
• Yajima N, Kasama T, Isozaki T, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52(6):1670–1675. doi:10.1002/(ISSN)1529-013115934075
   PubMed Web of Science ®Google Scholar
• Blaschke S, Koziolek M, Schwarz A, et al. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003;30(9):1918.12966591
   PubMed Web of Science ®Google Scholar
• Wang X, Xia S, Fu B. RNAseq analysis of synovial fibroblasts in human rheumatoid arthritis. Mol Med Rep. 2014;10(1):241–247. doi:10.3892/mmr.2014.218224788388
   PubMed Web of Science ®Google Scholar
• Sawai H, Park YW, He X, Goronzy JJ, Weyand CM. Fractalkine mediates T cell–dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 2007;56(10):3215–3225. doi:10.1002/(ISSN)1529-013117907166
   PubMed Web of Science ®Google Scholar
• Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum. 2007;56(8):2512–2522. doi:10.1002/(ISSN)1529-013117665439
   PubMed Web of Science ®Google Scholar
• Pingiotti E, Cipriani P, Marrelli A, et al. Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28− T Cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci. 2007;1107(1):32–41. doi:10.1196/annals.1381.00417804530
   PubMed Web of Science ®Google Scholar
• Asquith DL, Bryce SA, Nibbs RJB. Targeting cell migration in rheumatoid arthritis. Curr Opin Rheumatol. 2015;27(2):204–211. doi:10.1097/BOR.000000000000015025603038
   PubMed Web of Science ®Google Scholar
• Dennis G Jr, Holweg CTJ, Kummerfeld SK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16(2):R90. doi:10.1186/ar455525167216
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Koch AE, Tak PP. Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. Neth J Med. 2011;69(9):356–366.21978977
   PubMed Web of Science ®Google Scholar
• Loetscher P, Dewald B, Baggiolini M, Seitz M. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine. 1994;6(2):162–170. doi:10.1016/1043-4666(94)90038-88031999
   PubMed Web of Science ®Google Scholar
• Barsig J, Yam G, Lehner MD, Beume R. Methotrexate treatment suppresses local cytokine and chemokine production in rat adjuvant arthritis. Drugs Exp Clin Res. 2005;31(1):7–11.
   Google Scholar
• Volin MV, Campbell PL, Connors MA, Woodruff DC, Koch AE. The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol. 2002;73(2):84–92. doi:10.1006/exmp.2002.246012231210
   PubMed Web of Science ®Google Scholar
• Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. Clin Exp Immunol. 2003;133(1):132–138. doi:10.1046/j.1365-2249.2003.02192.x12823287
   PubMed Web of Science ®Google Scholar
• Kawashiri S-Y, Kawakami A, Iwamoto N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol. 2009;36(11):2397–2402. doi:10.3899/jrheum.09013219797510
   PubMed Web of Science ®Google Scholar
• Portalès P, Fabre S, Vincent T, et al. Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody. Immunology. 2009;128(1 Suppl):e738–e745. doi:10.1111/j.1365-2567.2009.03076.x19740335
   PubMed Web of Science ®Google Scholar
• Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311–1316. doi:10.1136/annrheumdis-2014-20602825398374
   PubMed Web of Science ®Google Scholar
• Kasama T, Isojima S, Umemura M, et al. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis. Rheumatol Int. 2014;34(3):429–433. doi:10.1007/s00296-013-2778-023670804
   PubMed Web of Science ®Google Scholar
• Allegretti M, Cesta MC, Garin A, Proudfoot AEI. Current status of chemokine receptor inhibitors in development. Immunol Lett. 2012;145(1):68–78. doi:10.1016/j.imlet.2012.04.00322698186
   PubMed Web of Science ®Google Scholar
• Striz I, Brabcova E, Kolesar L, Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond). 2014;126(9):593–612. doi:10.1042/CS2013049724450743
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Kraan MC, Smeets TJM, Zwinderman KH, Tak PP. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(8):715–721. doi:10.1136/ard.62.8.71512860725
   PubMed Web of Science ®Google Scholar
• Reynolds G, Cooles FAH, Isaacs JD, Hilkens CMU. Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother. 2014;10(4):822–837. doi:10.4161/hv.2791024535556
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Koch AE. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(1):5–13. doi:10.1038/nrrheum.2015.15726607389
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Kuritzkes DR. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol. 2013;3(1):51–57. doi:10.1016/j.coviro.2012.12.00223290628
   PubMed Web of Science ®Google Scholar
• Zhong C, Wang J, Li B, et al. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res. 2013;19(16):4433. doi:10.1158/1078-0432.CCR-13-094323812669
   PubMed Web of Science ®Google Scholar
• Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013;43(5):501–509. doi:10.1111/eci.2013.43.issue-523517338
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Gerlag DM, von Moltke L, et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum. 2009;60(12):3572–3581. doi:10.1002/art.v60:1219950299
   PubMed Web of Science ®Google Scholar
• Clucas AT, Shah A, Zhang Y, Chow VF, Gladue RP. Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. Clin Pharmacokinet. 2007;46(9):757–766. doi:10.2165/00003088-200746090-0000317713973
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008;58(7):1931–1939. doi:10.1002/art.v58:718576354
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov. 2009;8(1):23–33. doi:10.1038/nrd273419079127
   PubMed Web of Science ®Google Scholar
• van Kuijk AWR, Vergunst CE, Gerlag DM, et al. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. 2010;69(11):2013. doi:10.1136/ard.2010.13123520693270
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Gerlag DM, Smeets TJM, et al. A randomized controlled trial with an anti-CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2387–2392. doi:10.1002/art.2197516869001
   PubMed Web of Science ®Google Scholar
• Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol. 2005;174(11):7341. doi:10.4049/jimmunol.174.11.734115905581
   PubMed Web of Science ®Google Scholar
• Lebre MC, Vergunst CE, Choi IYK, et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS One. 2011;6(7):e21772. doi:10.1371/journal.pone.002177221747955
   PubMed Web of Science ®Google Scholar
• Kramer JM, Klimatcheva E, Rothstein TL. CXCL13 is elevated in Sjögren’s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol. 2013;94(5):1079–1089. doi:10.1189/jlb.011303623904442
   PubMed Web of Science ®Google Scholar
• Sharma A, Kiripolsky J, Klimatcheva E, et al. Early BAFF receptor blockade mitigates murine Sjögren’s syndrome: concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction. Clin Immunol. 2016;164:85–94. doi:10.1016/j.clim.2016.01.01526826598
   PubMed Web of Science ®Google Scholar
• Klimatcheva E, Pandina T, Reilly C, et al. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 2015;16(1):6. doi:10.1186/s12865-015-0068-125879435
   PubMed Web of Science ®Google Scholar
• Watanabe K, Penfold MET, Matsuda A, et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum. 2010;62(11):3211–3220. doi:10.1002/art.2765020617529
   PubMed Web of Science ®Google Scholar
• Jakobs BD, Spannagel L, Purvanov V, Uetz-von Allmen E, Matti C, Legler DF. Engineering of nanobodies recognizing the human chemokine receptor CCR7. Int J Mol Sci. 2019;20(10):2597. doi:10.3390/ijms20102597
   Web of Science ®Google Scholar
• Nanki T, Imai T, Kawai S. Fractalkine/CX3CL1 in rheumatoid arthritis. Mod Rheumatol. 2017;27(3):392–397. doi:10.1080/14397595.2016.121348127484962
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Umehara H, et al. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient Phase 1/2 study on rheumatoid arthritis. Mod Rheumatol. 2018;28(1):58–65. doi:10.1080/14397595.2017.133705628681650
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Umehara H, et al. Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis: 52-week results [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).
   Google Scholar
• Imai T, Yasuda N. Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway. Inflamm Regen. 2016;36(1):9. doi:10.1186/s41232-016-0017-229259682
   PubMedGoogle Scholar
• Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol. 2001;167(8):4686–4692. doi:10.4049/jimmunol.167.8.468611591799
   PubMed Web of Science ®Google Scholar
• Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett. 2004;569(1):99–104. doi:10.1016/j.febslet.2004.05.05615225616
   PubMed Web of Science ®Google Scholar
• Jenh C-H, Cox MA, Cui L, et al. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012;13:2. doi:10.1186/1471-2172-13-222233170
   PubMed Web of Science ®Google Scholar
• Kim B, Lee J-H, Jin WJ, Kim H-H, Ha H, Lee ZH. JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model. Eur J Pharmacol. 2018;823:1–10. doi:10.1016/j.ejphar.2018.01.03729378189
   PubMed Web of Science ®Google Scholar
• Broeren MGA, de Vries M, Bennink MB, et al. Disease-regulated gene therapy with anti-inflammatory interleukin-10 under the control of the CXCL10 promoter for the treatment of rheumatoid arthritis. Hum Gene Ther. 2015;27(3):244–254. doi:10.1089/hum.2015.127
   Web of Science ®Google Scholar
• Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol. 2002;169(5):2685. doi:10.4049/jimmunol.169.5.268512193742
   PubMed Web of Science ®Google Scholar
• Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-γ-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2002;168(11):5885. doi:10.4049/jimmunol.168.11.588512023393
   PubMed Web of Science ®Google Scholar
• Yellin M, Paliienko I, Balanescu A, et al. A Phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1730–1739. doi:10.1002/art.v64.622147649
   PubMed Web of Science ®Google Scholar
• Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol. 1997;182(1):106–114. doi:10.1002/(ISSN)1096-98969227349
   PubMed Web of Science ®Google Scholar
• Shahrara S, Proudfoot AEI, Park CC, et al. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol. 2008;180(5):3447. doi:10.4049/jimmunol.180.5.344718292571
   PubMed Web of Science ®Google Scholar
• Brühl H, Cihak J, Plachý J, et al. Targeting of Gr-1+, CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum. 2007;56(9):2975–2985. doi:10.1002/(ISSN)1529-013117763443
   PubMed Web of Science ®Google Scholar
• Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med. 1997;186(10):1757–1762. doi:10.1084/jem.186.10.17579362535
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Kameda H. What is the future of CCR5 antagonists in rheumatoid arthritis? Arthritis Res Ther. 2012;14(2):114. doi:10.1186/ar377522494450
   PubMed Web of Science ®Google Scholar
• Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol. 1998;72(6):4962–4969. doi:10.1128/JVI.72.6.4962-4969.19989573265
   PubMed Web of Science ®Google Scholar
• Duan H, Yang P, Fang F, Ding S, Xiao W. CCR5 small interfering RNA ameliorated joint inflammation in rats with adjuvant-induced arthritis. Immunol Lett. 2014;162(2, Part B):258–263. doi:10.1016/j.imlet.2014.09.01825300256
   PubMed Web of Science ®Google Scholar
• Vierboom MPM, Zavodny PJ, Chou C-C, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. 2005;52(2):627–636. doi:10.1002/art.2085015693002
   PubMed Web of Science ®Google Scholar
• Zapico I, Coto E, Rodríguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 2000;1(4):288–289. doi:10.1038/sj.gene.636367311196706
   PubMed Web of Science ®Google Scholar
• Gerlag DM, Hollis S, Layton M, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010;62(11):3154–3160. doi:10.1002/art.2765220662070
   PubMed Web of Science ®Google Scholar
• Shahrara S, Proudfoot AEI, Woods JM, et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. 2005;52(6):1907–1919. doi:10.1002/art.2103315934086
   PubMed Web of Science ®Google Scholar
• Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett. 1997;57(1–3):117–120. doi:10.1016/S0165-2478(97)00075-89232436
   PubMed Web of Science ®Google Scholar
• Booth G, Newham P, Barlow R, Raines S, Zheng B, Han S. Gene expression profiles at different stages of collagen-induced arthritis. Autoimmunity. 2008;41(7):512–521. doi:10.1080/0891693080209521018608173
   PubMed Web of Science ®Google Scholar
• Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol. 1998;20(1):133–147. doi:10.1007/BF008320039836373
   PubMed Web of Science ®Google Scholar
• Amat M, Benjamim CF, Williams LM, et al. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol. 2006;149(6):666–675. doi:10.1038/sj.bjp.070691217016504
   PubMed Web of Science ®Google Scholar
• Ronald PG, Matthew FB, Samuel HZ. CCR1 antagonists: what have we learned from clinical trials. Curr Top Med Chem. 2010;10(13):1268–1277. doi:10.2174/15680261079156123720536425
   PubMed Web of Science ®Google Scholar
• Kivitz A, Maciag P, Gulati P, et al. THU0109 Lack of efficacy of CCR1 antagonist BMS-817399 in patients with moderate to severe rheumatoid arthritis: results of 12-week proof-of-concept study. Ann Rheum Dis. 2014;73(Suppl 2):215. doi:10.1136/annrheumdis-2014-eular.3871
   Web of Science ®Google Scholar
• Naya A, Ishikawa M, Matsuda K, et al. Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg Med Chem. 2003;11(6):875–884. doi:10.1016/S0968-0896(02)00559-X12614873
   PubMed Web of Science ®Google Scholar
• Tak PP, Balanescu A, Tseluyko V, et al. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013;72(3):337. doi:10.1136/annrheumdis-2011-20160522589376
   PubMed Web of Science ®Google Scholar
• Dairaghi DJ, Zhang P, Wang Y, et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther. 2011;89(5):726–734. doi:10.1038/clpt.2011.3321451509
   PubMed Web of Science ®Google Scholar
• Jiao Z, Wang W, Jia R, et al. Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol. 2007;36(6):428–433. doi:10.1080/0300974070148280018092263
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood. 2006;108(2):426–431. doi:10.1182/blood-2006-01-017716537800
   PubMed Web of Science ®Google Scholar
• Pablos JL, Santiago B, Galindo M, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003;170(4):2147–2152. doi:10.4049/jimmunol.170.4.214712574387
   PubMed Web of Science ®Google Scholar
• Shi K, Hayashida K, Kaneko M, et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2001;166(1):650. doi:10.4049/jimmunol.166.1.65011123349
   PubMed Web of Science ®Google Scholar
• Gong JH, Yan R, Waterfield JD, Clark-Lewis I. Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy. Rheumatology. 2003;43(1):39–42. doi:10.1093/rheumatology/keg45914566030
   PubMed Web of Science ®Google Scholar
• Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol. 2010;88(1):41–55. doi:10.1189/jlb.100967120360402
   PubMed Web of Science ®Google Scholar
• Matsukawa A, Yoshimura T, Fujiwara K, Maeda T, Ohkawara S, Yoshinaga M. Involvement of growth-related protein in lipopolysaccharide-induced rabbit arthritis: cooperation between growth-related protein and IL-8, and interrelated regulation among TNFalpha, IL-1, IL-1 receptor antagonist, IL-8, and growth-related protein. Lab Invest. 1999;79(5):591–600.10334570
   PubMed Web of Science ®Google Scholar